276 related articles for article (PubMed ID: 33392702)
1. A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
Oliva S; De Paoli L; Ruggeri M; Caltagirone S; Troia R; Oddolo D; D'Agostino M; Gilestro M; Mina R; Saraci E; Margiotta Casaluci G; Genuardi E; Bringhen S; Boccadoro M; Omedé P
Ann Hematol; 2021 Feb; 100(2):437-443. PubMed ID: 33392702
[TBL] [Abstract][Full Text] [Related]
2. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetic Profile in Monoclonal Gammopathy of Undetermined Significance, Smoldering and Symptomatic Multiple Myeloma: A Study of 1087 Patients with Highly Purified Plasma Cells.
Tang G; Wu Y; Lin P; Toruner GA; Hu S; Li S; Qazilbash MH; Orlowski RZ; Ye C; Xu J; Nahmod KA; Medeiros LJ; Tang Z
Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067393
[TBL] [Abstract][Full Text] [Related]
4. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
Front Immunol; 2021; 12():792609. PubMed ID: 34880879
[TBL] [Abstract][Full Text] [Related]
5. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients.
Visram A; Soof C; Rajkumar SV; Kumar SK; Bujarski S; Spektor TM; Kyle RA; Berenson JR; Dispenzieri A
Blood Cancer J; 2021 Jun; 11(6):120. PubMed ID: 34168119
[TBL] [Abstract][Full Text] [Related]
6. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.
Salem DA; Korde N; Venzon DJ; Liewehr DJ; Maric I; Calvo KR; Braylan R; Tembhare PR; Yuan CM; Landgren CO; Stetler-Stevenson M
Leuk Lymphoma; 2018 Jan; 59(1):178-186. PubMed ID: 28540748
[TBL] [Abstract][Full Text] [Related]
7. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability.
Dutta AK; Fink JL; Grady JP; Morgan GJ; Mullighan CG; To LB; Hewett DR; Zannettino ACW
Leukemia; 2019 Feb; 33(2):457-468. PubMed ID: 30046162
[TBL] [Abstract][Full Text] [Related]
8. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
[TBL] [Abstract][Full Text] [Related]
9. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
[TBL] [Abstract][Full Text] [Related]
10. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance.
Drach J; Angerler J; Schuster J; Rothermundt C; Thalhammer R; Haas OA; Jäger U; Fiegl M; Geissler K; Ludwig H; Huber H
Blood; 1995 Nov; 86(10):3915-21. PubMed ID: 7579361
[TBL] [Abstract][Full Text] [Related]
11. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
Mateos MV; Landgren O
Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
[TBL] [Abstract][Full Text] [Related]
12. Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation.
Chang H; Yeung J; Xu W; Ning Y; Patterson B
Br J Haematol; 2006 Sep; 134(6):613-5. PubMed ID: 16889615
[TBL] [Abstract][Full Text] [Related]
13. Burden of cytogenetically abnormal plasma cells in light chain amyloidosis and their prognostic relevance.
Kim SY; Im K; Park SN; Kim JA; Yoon SS; Lee DS
Leuk Res; 2016 May; 44():45-52. PubMed ID: 27015231
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma.
Merz M; Hielscher T; Schult D; Mai EK; Raab MS; Hillengass J; Seckinger A; Hose D; Granzow M; Jauch A; Goldschmidt H
Leukemia; 2020 Apr; 34(4):1192-1196. PubMed ID: 31712777
[No Abstract] [Full Text] [Related]
16. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark.
Christensen JH; Abildgaard N; Plesner T; Nibe A; Nielsen O; Sørensen AG; Kerndrup GB;
Cancer Genet Cytogenet; 2007 Apr; 174(2):89-99. PubMed ID: 17452249
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
18. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
[No Abstract] [Full Text] [Related]
19. Stromal alterations in patients with monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma.
Bogun L; Koch A; Scherer B; Fenk R; Maus U; Bormann F; Köhrer K; Petzsch P; Wachtmeister T; Zukovs R; Dietrich S; Haas R; Schroeder T; Jäger P; Geyh S
Blood Adv; 2024 May; 8(10):2575-2588. PubMed ID: 38241490
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
